An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Trial ID or NCT#
This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific gene profile involving the ALK gene after failure of one previous chemotherapy regimen that included one platinum drug.
Phase 3, Randomized, Open-label Study Of The Efficacy And Safety Of Pf-02341066 Versus Standard Of Care Chemotherapy (Pemetrexed Or Docetaxel) In Patients With Advanced Non-small Cell Lung Cancer (Nsclc) Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus
- - histologically or cytologically proven diagnosis of non-small cell lung cancer - positive for the ALK fusion gene (test provided by a central laboratory) - must have had disease progression after only one prior chemotherapy and that regimen but must have included one platinum drug - tumors must be measurable
- - prior treatment with PF-02341066 - current treatment in another clinical trial
Contact us to find out if this trial is right for you.
Cancer Clinical Trials Office